The FDA announced on March 27, 2026, that Appco Pharma LLC is recalling Prazosin Hydrochloride Capsels due to the detection of N-nitroso-prazosin impurity C above acceptable limits. The agency said consumers should contact the company for a refund.
How to tell if you have it
- Brand: Appco Pharma
- Product: Prazosin Hydrochloride Capsules, USP, 1mg, 100-count bottle
- NDC: 70377-066-11
- Lots: 2404160C (Exp. 2026/MAR), 2406253C (Exp. 2026/MAY), 2407311C (Exp. 2026/JUL), 2407312C (Exp. 2026/JUL), 2408350C (Exp. 2026/JUL), 2505172C (Exp. 2027/MAY), 2506191C (Exp. 2027/JUN)
- Quantity: 88,008 bottles
The hazard
The recall is due to cGMP deviations involving the detection of N-nitroso-prazosin impurity C above acceptable limits. The FDA's FAERS database contains 1,308 adverse-event reports naming this product, with 824 marked serious and 90 listing a death.
Context
GovInfoNow's records show Appco Pharma LLC has two other recalls on record since January 7, 2020, including a January 16, 2025, recall for Venlafaxine tablets and a January 7, 2020, recall for Ranitidine capsules. Other recent recalls of similar products include an October 16, 2025, Amerisource Health Prazosin Capsules Recall for N-nitroso impurity risk and a May 14, 2026, Asclemed Duloxetine Capsules Recall for nitrosamine impurity risk.